OBI-833/OBI-821

DRUG3 trials

Sponsors

OBI Pharma, Inc, National Taiwan University Hospital, Chang Gung Memorial Hospital

Conditions

Chemotherapy EffectCholangiocarcinomaEsophageal CancerImmunotherapyMetastatic Breast CancerMetastatic Colorectal CancerMetastatic Gastric CancerMetastatic Lung Cancer

Phase 1

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

CompletedNCT02310464

OBI Pharma, IncMetastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Gastric Cancer +1

Start: 2015-12-22End: 2021-02-02Updated: 2022-10-03

Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin

Not yet recruitingNCT06490198

Chang Gung Memorial HospitalChemotherapy Effect, Cholangiocarcinoma, Immunotherapy

Start: 2024-07-31End: 2027-07-31Target: 30Updated: 2024-07-08

Phase 2

To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence

National Taiwan University HospitalEsophageal Cancer

Start: 2022-06-02End: 2025-06-30Target: 60Updated: 2023-11-15